Latest close
Data unavailable
No price in range
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Paradigm Biocapital Advisors | 0.61% | 4,951,856 | NEW |
Source: SEC Form 13F filings for the quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. 13F filings cover long positions only and arrive up to 45 days after quarter-end. Fund counts here aggregate every share class mapped to this ticker; research headlines cite filer counts as they stood at publication, so a count here can differ from a headline by a holder (see Methodology, "How holder counts are counted").
| Shares short · Sep 15, 2026 | 15,993,814 |
| Days to cover | 9.10 |
Shares short at recent settlements — Jun 30, 2026: 12.6M · Jul 15, 2026: 14.7M · Jul 31, 2026: 16.3M · Aug 14, 2026: 16.4M · Aug 31, 2026: 16.4M · Sep 15, 2026: 16.0M.
Source: FINRA Equity Short Interest (biweekly settlement data).
Data unavailable — no Form 4 transactions for this ticker were parsed in the 90 days to Oct 14, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Oct 3, 2026).
This stock does not currently pass any tracked screen.
Also held by the tracked funds that hold ACHV: REVOLUTION MEDICINES INC (RVMD) · TANGO THERAPEUTICS INC (TNGX) · Oruka Therapeutics, Inc. (ORKA) · INSMED Inc (INSM) · CYTOKINETICS INC (CYTK) · STRUCTURE THERAPEUTICS INC (GPCR) · Edgewise Therapeutics, Inc. (EWTX) · SPYRE THERAPEUTICS INC (SYRE) · BELITE BIO, INC (BLTE) · ALNYLAM PHARMACEUTICALS, INC. (ALNY).
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.